vs
Side-by-side financial comparison of 908 Devices Inc. (MASS) and Mirion Technologies, Inc. (MIR). Click either name above to swap in a different company.
Mirion Technologies, Inc. is the larger business by last-quarter revenue ($277.4M vs $17.4M, roughly 16.0× 908 Devices Inc.). 908 Devices Inc. runs the higher net margin — 24.0% vs 6.2%, a 17.8% gap on every dollar of revenue. On growth, 908 Devices Inc. posted the faster year-over-year revenue change (21.2% vs 9.1%). Mirion Technologies, Inc. produced more free cash flow last quarter ($63.2M vs $1.3M). Over the past eight quarters, 908 Devices Inc.'s revenue compounded faster (53.0% CAGR vs 20.0%).
908 Devices Inc. develops and manufactures portable, high-performance mass spectrometry devices and analytical solutions. Its products serve use cases across life science research, biopharmaceutical manufacturing, public safety, forensics, and industrial process monitoring, catering to global customers including research institutions, pharmaceutical firms and government agencies.
Mirion Technologies, Inc. is a global provider of radiation detection, monitoring, and safety solutions. Its core offerings include personal dosimetry systems, radiation imaging equipment, and risk management software, serving nuclear power, healthcare, defense, and industrial sectors across North America, Europe, and the Asia Pacific.
MASS vs MIR — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $17.4M | $277.4M |
| Net Profit | $4.2M | $17.3M |
| Gross Margin | 52.7% | 48.8% |
| Operating Margin | 17.8% | 9.2% |
| Net Margin | 24.0% | 6.2% |
| Revenue YoY | 21.2% | 9.1% |
| Net Profit YoY | 121.5% | 15.3% |
| EPS (diluted) | $0.09 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.4M | $277.4M | ||
| Q3 25 | $14.0M | $223.1M | ||
| Q2 25 | $13.0M | $222.9M | ||
| Q1 25 | $11.8M | $202.0M | ||
| Q4 24 | $14.3M | $254.3M | ||
| Q3 24 | $14.5M | $206.8M | ||
| Q2 24 | $11.5M | $207.1M | ||
| Q1 24 | $7.4M | $192.6M |
| Q4 25 | $4.2M | $17.3M | ||
| Q3 25 | $-15.0M | $2.9M | ||
| Q2 25 | $-13.3M | $8.3M | ||
| Q1 25 | $43.6M | $300.0K | ||
| Q4 24 | $-19.4M | $15.0M | ||
| Q3 24 | $-29.3M | $-13.6M | ||
| Q2 24 | $-12.5M | $-11.7M | ||
| Q1 24 | $-10.9M | $-25.8M |
| Q4 25 | 52.7% | 48.8% | ||
| Q3 25 | 52.5% | 46.8% | ||
| Q2 25 | 48.9% | 46.0% | ||
| Q1 25 | 47.0% | 47.6% | ||
| Q4 24 | 46.5% | 48.1% | ||
| Q3 24 | 53.6% | 44.9% | ||
| Q2 24 | 53.8% | 47.0% | ||
| Q1 24 | 52.4% | 45.2% |
| Q4 25 | 17.8% | 9.2% | ||
| Q3 25 | -116.6% | 3.3% | ||
| Q2 25 | -116.3% | 4.4% | ||
| Q1 25 | -93.6% | 4.3% | ||
| Q4 24 | -116.8% | 11.4% | ||
| Q3 24 | -168.7% | -0.8% | ||
| Q2 24 | -74.5% | 1.1% | ||
| Q1 24 | -102.5% | -2.5% |
| Q4 25 | 24.0% | 6.2% | ||
| Q3 25 | -107.0% | 1.3% | ||
| Q2 25 | -102.1% | 3.7% | ||
| Q1 25 | 370.2% | 0.1% | ||
| Q4 24 | -135.6% | 5.9% | ||
| Q3 24 | -201.8% | -6.6% | ||
| Q2 24 | -109.5% | -5.6% | ||
| Q1 24 | -147.1% | -13.4% |
| Q4 25 | $0.09 | $0.07 | ||
| Q3 25 | $-0.41 | $0.01 | ||
| Q2 25 | $-0.37 | $0.03 | ||
| Q1 25 | $1.23 | $0.00 | ||
| Q4 24 | $-0.58 | $0.08 | ||
| Q3 24 | $-0.84 | $-0.07 | ||
| Q2 24 | $-0.37 | $-0.06 | ||
| Q1 24 | $-0.33 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $113.0M | $412.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $143.7M | $1.9B |
| Total Assets | $190.1M | $3.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $113.0M | $412.3M | ||
| Q3 25 | $112.1M | $933.2M | ||
| Q2 25 | $118.6M | $262.6M | ||
| Q1 25 | $124.3M | $185.8M | ||
| Q4 24 | $69.6M | $175.2M | ||
| Q3 24 | $71.7M | $133.3M | ||
| Q2 24 | $77.4M | $122.2M | ||
| Q1 24 | $134.2M | $120.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | $444.8M | ||
| Q2 25 | — | $444.9M | ||
| Q1 25 | — | $686.6M | ||
| Q4 24 | — | $686.4M | ||
| Q3 24 | — | $685.1M | ||
| Q2 24 | — | $684.1M | ||
| Q1 24 | — | $685.5M |
| Q4 25 | $143.7M | $1.9B | ||
| Q3 25 | $136.3M | $1.8B | ||
| Q2 25 | $148.8M | $1.5B | ||
| Q1 25 | $159.4M | $1.5B | ||
| Q4 24 | $114.6M | $1.5B | ||
| Q3 24 | $131.0M | $1.5B | ||
| Q2 24 | $156.4M | $1.5B | ||
| Q1 24 | $156.9M | $1.5B |
| Q4 25 | $190.1M | $3.6B | ||
| Q3 25 | $190.9M | $3.5B | ||
| Q2 25 | $191.7M | $2.7B | ||
| Q1 25 | $196.0M | $2.6B | ||
| Q4 24 | $159.5M | $2.6B | ||
| Q3 24 | $178.3M | $2.7B | ||
| Q2 24 | $208.8M | $2.6B | ||
| Q1 24 | $189.8M | $2.6B |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.45× | ||
| Q1 24 | — | 0.47× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.3M | $73.0M |
| Free Cash FlowOCF − Capex | $1.3M | $63.2M |
| FCF MarginFCF / Revenue | 7.6% | 22.8% |
| Capex IntensityCapex / Revenue | 0.0% | 3.5% |
| Cash ConversionOCF / Net Profit | 0.32× | 4.22× |
| TTM Free Cash FlowTrailing 4 quarters | $-24.7M | $106.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3M | $73.0M | ||
| Q3 25 | $-4.2M | $22.3M | ||
| Q2 25 | $-5.8M | $12.4M | ||
| Q1 25 | $-15.0M | $35.6M | ||
| Q4 24 | $-2.2M | $60.8M | ||
| Q3 24 | $-5.6M | $17.1M | ||
| Q2 24 | $-13.0M | $15.2M | ||
| Q1 24 | $-9.4M | $6.0M |
| Q4 25 | $1.3M | $63.2M | ||
| Q3 25 | $-4.9M | $13.0M | ||
| Q2 25 | $-5.9M | $3.6M | ||
| Q1 25 | $-15.2M | $27.1M | ||
| Q4 24 | $-2.4M | $49.1M | ||
| Q3 24 | $-5.8M | $3.9M | ||
| Q2 24 | $-13.7M | $4.1M | ||
| Q1 24 | $-10.3M | $-6.8M |
| Q4 25 | 7.6% | 22.8% | ||
| Q3 25 | -34.9% | 5.8% | ||
| Q2 25 | -45.3% | 1.6% | ||
| Q1 25 | -128.9% | 13.4% | ||
| Q4 24 | -17.0% | 19.3% | ||
| Q3 24 | -39.7% | 1.9% | ||
| Q2 24 | -119.4% | 2.0% | ||
| Q1 24 | -138.2% | -3.5% |
| Q4 25 | 0.0% | 3.5% | ||
| Q3 25 | 4.9% | 4.2% | ||
| Q2 25 | 0.9% | 3.9% | ||
| Q1 25 | 1.4% | 4.2% | ||
| Q4 24 | 1.3% | 4.6% | ||
| Q3 24 | 1.1% | 6.4% | ||
| Q2 24 | 5.6% | 5.4% | ||
| Q1 24 | 12.2% | 6.6% |
| Q4 25 | 0.32× | 4.22× | ||
| Q3 25 | — | 7.69× | ||
| Q2 25 | — | 1.49× | ||
| Q1 25 | -0.34× | 118.67× | ||
| Q4 24 | — | 4.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MASS
| Products | $14.3M | 82% |
| Services | $3.0M | 18% |
MIR
| Transferred Over Time | $96.6M | 35% |
| Services | $65.0M | 23% |
| Cancer Care | $61.8M | 22% |
| Labs And Research | $34.0M | 12% |
| Other Care | $20.7M | 7% |
